Insightful Non-Alcoholic Steatohepatitis Treatment Market Report 2025 – For Product, Marketing, and Strategy Teams

 This report is designed for companies and decision-makers seeking actionable insights on market size, growth, trends, and competitive strategies to drive expansion and success in the Non-Alcoholic Steatohepatitis Treatment industry.

How has the non-alcoholic steatohepatitis treatment market size changed in recent years, and what is the outlook ahead?
The non-alcoholic steatohepatitis treatment market size has grown exponentially in recent years. It will grow from $2.6 billion in 2024 to $3.6 billion in 2025 at a compound annual growth rate (CAGR) of 38.5%. The growth in the historic period can be attributed to rising prevalence of NASH, growing awareness and diagnosis, lifestyle changes and obesity epidemic, clinical research, healthcare infrastructure and access, regulatory support and clinical trials.

The non-alcoholic steatohepatitis treatment market size is expected to see exponential growth in the next few years. It will grow to $13.83 billion in 2029 at a compound annual growth rate (CAGR) of 40.0%. The growth in the forecast period can be attributed to advancements in drug development, increased disease awareness, rising prevalence and risk factor, shift towards personalized medicine. Major trends in the forecast period include patient-centric approach, technological advancements, targeted therapies, regulatory landscape, advancements in research.

Download Your Free Sample PDF:
Non-Alcoholic Steatohepatitis Treatment Market Report 2025, Trend Sample

What are the top economic and technological drivers pushing non-alcoholic steatohepatitis treatment market growth?
An increased prevalence of insulin resistance has propelled the growth of the non-alcoholic steatohepatitis treatment market going forward. Insulin resistance occurs when muscles, fat, and liver cells do not respond adequately to insulin and cannot easily absorb glucose from the blood, causing high blood sugar. These are linked to an unhealthy lifestyle, excessive sugar consumption, and genetics. The use of insulin resistance has multiplied due to increased diabetes and other liver-related issues, which are treated with non-alcoholic steatohepatitis treatment. For instance, January 2022, according to a report from International Diabetes Federation, a Belgium-based global diabetes community, diabetes affects 537 million individuals (20-79 years old), accounting for one in every ten, which is expected to increase to 643 million by 2030 and 783 million by 2045. Furthermore, in January 2024, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, expected new cases of liver cancer to reach 41,630 in 2024 compared to 41,210 in 2023., Therefore, an increase in the prevalence of insulin resistance due to multiple liver and diabetes diseases will drive the non-alcoholic steatohepatitis treatment market.

How is the non-alcoholic steatohepatitis treatment market segmented by product, application, and end-user?
The non-alcoholic steatohepatitis treatment market covered in this report is segmented –

1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types
2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures
3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users

Subsegments:
1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.
2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH
3) By Elafibranor: Elafibranor-Based Treatments
4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations
5) By Obeticholic Acid: Other Formulations Of Obeticholic Acid
6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies

View The Full Market Report:
Non-Alcoholic Steatohepatitis Treatment Market Report 2025, Trend

Which major trends are influencing the growth of the non-alcoholic steatohepatitis treatment industry?
The development of the non-alcoholic steatohepatitis (NASH) drug is a key trend gaining popularity in the non-alcoholic steatohepatitis treatment market. Many companies are investing in developing innovative drugs for the treatment of liver diseases with reduced side effects of the drugs. For instance, in May 2022, Pfizer Inc., an American pharmaceutical and biotechnology company, received a grant from U.S. Food and Drug Administration (FDA) for fast-track designation to facilitate the development of the non-alcoholic steatohepatitis (NASH) drug, namely ervogastat and clesacostat. Fast Track is a process designed to Pfizer’s investigational combination therapy for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis named as, ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi).

Which leading companies are dominating the non-alcoholic steatohepatitis treatment market landscape?
Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Immuron Ltd., Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG

Which geographic areas are expected to offer the highest growth opportunities in thenon-alcoholic steatohepatitis treatment market?
North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2024. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Can Companies Use The Non-Alcoholic Steatohepatitis Treatment Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.

Purchase The Report And Get A Swift Delivery:
Non-Alcoholic Steatohepatitis Treatment Market Report 2025, Trend

Need Customized Data On Non-Alcoholic Steatohepatitis Treatment Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you're entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.

Request Customized Data:
Non-Alcoholic Steatohepatitis Treatment Market Report 2025, Trend Customise

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.

Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Contact Us:

The Business Research Company

Market Research Reports

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info


Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company